Jowell Global Ltd. — FY2023 Form 20-F
Reporting period: Fiscal year ended December 31, 2023. Although the request references 2023 Q4, this is an annual filing; the supplied text does not provide standalone fourth-quarter results. Amounts are in U.S. dollars unless stated otherwise.
Business context
Jowell operates a China-focused e-commerce and retail business selling cosmetics, health and nutritional supplements, and household products through online direct sales, authorized stores, third-party merchants, and livestream marketing. Its principal operations are conducted by Shanghai Juhao, a variable interest entity (VIE) consolidated through contractual arrangements. The company reported 2.48 million registered VIP members, 270 platform merchants, and 26,746 authorized Love Home Stores at year-end.
Financial performance and position
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $160.0 million | $210.0 million |
| Gross profit / margin | $3.3 million / 2.0% | $6.2 million / 3.0% |
| Operating loss / margin | $10.9 million / (6.8%) | $12.0 million / (5.7%) |
| Net loss | $11.5 million / (7.2%) of revenue | $11.5 million / (5.5%) of revenue |
| Operating cash flow | $(13.5) million | $(12.0) million |
- Revenue mix: Cosmetics $55.1 million (down 44.5%); health and nutritional supplements $22.6 million (down 43.4%); household products $81.8 million (up 15.8%). Household products increased to 51.1% of revenue.
- Cash and liquidity: Cash was $1.25 million at year-end, down from $13.72 million; restricted cash was nil versus $3.0 million. Current assets were $26.66 million and current liabilities $9.05 million, implying working capital of about $17.61 million. The filing’s liquidity discussion also cites working capital of $16.6 million, an inconsistency to verify.
- Debt and obligations: Short-term loan balance was $0.42 million, compared with $2.46 million in 2022. Operating lease liabilities totaled $1.98 million. Total liabilities were $10.08 million.
- Other cash-flow items: Investing cash outflow was $0.04 million and financing cash outflow was $1.63 million. The company reported an approximately $0.45 million loss on its Hongrun investment. The allowance for receivable credit losses rose to $0.56 million from $0.08 million.
Material changes versus FY2022
Revenue contracted 23.8%, with sharp declines in cosmetics and supplements. Management attributed the cosmetics decline to lower unit volumes and prices, including weaker demand for premium brands; supplements revenue fell mainly as the company shifted toward lower-priced products. Household revenue grew, partly from higher-priced products. Cost of revenue fell more slowly than sales, compressing gross margin by about one percentage point. Operating expenses declined 23.0%, helping narrow the operating loss, but the net loss was essentially unchanged and operating cash use increased. Marketing expense fell in dollars but rose to 4.9% of revenue from 4.2%. Customer-placed orders fell to 131,616 from 184,079; repeat customers declined to 48,591 from 62,936.
Outlook, risks and unusual items
- Management aims to reduce costs and move toward profitability over the next one to two years, including by controlling promotions and marketing. It says cash on hand, bank borrowing, and potential equity financing should cover requirements for at least 12 months from issuance of the financial statements. This is not a quantified revenue or earnings forecast.
- At March 31, 2024, the company reported approximately $0.54 million cash; it said 47% of year-end receivables had been collected and 81% of supplier advances had been utilized. These updates are important to the liquidity assessment.
- The company uses a VIE structure, which may be challenged under PRC law; it also faces regulatory, foreign-exchange, data-security, competition, delivery, product-quality, and thin-trading risks. The filing says it had required operating permits and was not then subject to a CAC cybersecurity review, based on PRC counsel’s advice.
- Longrich Group, controlled by a major shareholder, supplied about 20% of 2023 purchases ($34.3 million); related-party purchases and leases present conflict-of-interest risks. The company also identified two other major suppliers, at approximately 11% and 10% of purchases.
- Management concluded disclosure controls and internal control over financial reporting were ineffective at December 31, 2023. Two material weaknesses were disclosed: insufficient in-house U.S. GAAP/SEC reporting expertise and inadequate segregation of access privileges in the Yongyou system. Remediation is planned but not assured.
- The 2023 financial statements received an unmodified U.S. GAAP audit opinion from Enrome LLP. Enrome replaced Marcum Asia in December 2023; the filing says the auditor was subject to PCAOB inspection. A 1-for-16 share consolidation in October 2023 was intended to regain Nasdaq’s minimum bid-price compliance; the company reported regaining compliance in November.
- No material legal proceedings were reported. The company has not paid dividends and does not expect to do so in the foreseeable future.
Investor verification priorities
- Reconcile the stated working-capital figures and assess the sharp decline in cash, negative operating cash flow, and the company’s liquidity plan against the March 31, 2024 cash update.
- Track collections of receivables and use or recovery of supplier advances, especially related-party advances, and review the increased credit-loss allowance.
- Verify progress in remediating both material weaknesses and whether controls become effective in subsequent filings.
- Review related-party purchases, leases, outstanding balances, approval processes, and the continued dependence on Longrich and other key suppliers.
- Assess whether management’s cost-reduction plan can restore margins amid falling sales, changing product mix, and reduced order volume.
- Understand the VIE contractual and PRC regulatory risks, restrictions on moving cash out of China, dual-class voting control, and potential dilution from future financing.